OTLK

Outlook Therapeutics, Inc. - Common Stock (OTLK)

About Outlook Therapeutics, Inc. - Common Stock (OTLK)

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Details

Daily high

$0.47

Daily low

$0.41

Price at open

$0.46

52 Week High

$2.54

52 Week Low

$0.16

Market cap

112.5M

Dividend yield

Volume

4.2M

Avg. volume

3.8M

P/E ratio

-.42

Outlook Therapeutics, Inc. - Common Stock News